Review:
Denosumab
overall review score: 4.2
⭐⭐⭐⭐⭐
score is between 0 and 5
Denosumab is a monoclonal antibody medication used primarily to treat osteoporosis and other bone-loss conditions. It works by inhibiting RANKL (receptor activator of nuclear factor kappa-Β ligand), which plays a key role in osteoclast formation, leading to decreased bone resorption and increased bone density.
Key Features
- Injectable biologic therapy administered subcutaneously
- Targets RANKL to inhibit osteoclast activity
- Used for osteoporosis, bone metastases, and hypercalcemia of malignancy
- Shown to significantly reduce the risk of fractures
- Typically given every 6 months for osteoporosis treatment
Pros
- Effective in increasing bone density and reducing fracture risk
- Convenient dosing schedule (every six months for osteoporosis)
- Has been well-studied with demonstrated efficacy
- May be used in patients who cannot tolerate bisphosphonates
Cons
- Potential side effects include hypocalcemia, infections, and rare occurrences of osteonecrosis of the jaw
- Requires regular injections and medical supervision
- Long-term safety data is still being evaluated
- Not suitable for use in certain patients with hypocalcemia or specific health conditions